경두개 자기 자극 시스템 시장 : 유형별, 용도별, 연령층별, 최종 사용자별, 지역별, 기회, 예측(2018-2032년)

Global transcranial magnetic stimulation system market is projected to witness a CAGR of 10.05% during the forecast period 2025-2032, growing from USD 1.51 billion in 2024 to USD 3.25 billion in 2032. The global transcranial magnetic stimulation system market is expected to keep growing at a robust pace during the forecast period, owing to the increasing prevalence of Alzheimer's disease, Parkinson's disease, and other neurological disorders.

A transcranial magnetic stimulation system is a non-invasive medical device that uses electromagnetic fields to stimulate specific brain areas. It is primarily used to treat neurological and psychiatric disorders such as major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), especially in patients who do not respond to conventional treatments. According to a Lancet neurology report, neurological conditions affect 43% of the world's population. The main participants include Parkinson's disease, neonatal encephalopathy, migraine, Alzheimer's disease, and diabetic neuropathy. Neurodevelopmental and pediatric disorders account for nearly 20% of the disease burden. Advancements in non-invasive therapeutic techniques and growing awareness of transcranial magnetic stimulation as an effective treatment option are driving the growth of the transcranial magnetic stimulation systems market. For instance, in March 2024, Neuronetics, Inc. announced the United States Food and Drug Administration clearance for its NeuroStar Advanced Therapy for use as an adjunct treatment for major depressive disorder in adolescents aged 15-21. NeuroStar becomes the first FDA-cleared TMS treatment for this age group, marking its fourth FDA clearance. With depression rates among adolescents rising, particularly post-COVID-19, NeuroStar offers a promising first-line treatment option supported by real-world data and response rates comparable to those in adults. This advancement has the potential to reshape how depression is treated in younger populations.

Increasing Prevalence of Mental Health Disorders Boosts Market Growth

The rising incidence of mental health disorders is a key growth driver for the global transcranial magnetic stimulation systems market, as depression, anxiety, epilepsy, Alzheimer's disease, and many other mental illnesses are on the rise across the globe. Additionally, demand has risen for innovative and non-invasive treatment options. TMS is gaining popularity as the best alternative in the treatment of patients who develop resistance to conventional therapies. The increasing burden of mental health disorders and the limitations of traditional treatments call for alternative therapies in the approach to treating these common disorders. This market is further supported by increasing acceptance among healthcare providers and patients. For instance, in January 2024, BrainsWay Ltd launched two feasibility studies to evaluate its new rotational field transcranial magnetic stimulation technology, focusing on stroke rehabilitation and OCD. The Deep TMS 360 system, which enhances neuron activation through a rotating electric field generated by two perpendicular coils, aims to overcome the limitations of traditional TMS systems.

Rising Awareness and Technological Advancement Drives Market Growth

Awareness and technological advantages are major growth drivers for the transcranial magnetic stimulation systems market. Increased awareness about the safety and effectiveness of TMS as a treatment option for various mental health diseases is creating high growth opportunities for TMS systems among healthcare professionals and patients. TMS is emerging as an alternative therapy for patients who do not respond to conventional treatments, and this has also driven the demand for TMS solutions. Additionally, technological innovations such as integrating artificial intelligence (AI) for more accurate treatments have further helped increase the prospects of the market. Advanced TMS systems now provide more customized and focused treatments, and patients may receive a wide range of disorders for treatment. Such developments, along with the increasing recognition of TMS as a promising treatment, are also driving market growth. For instance, in April 2024, Soterix Medical Inc. launched the MxN-GO EEG, a mobile, untethered system combining High-Definition transcranial Electrical Stimulation (HD-tES) and electroencephalogram system. Designed for mobile and natural environments, the lightweight, wire-free system offers 33 stimulation channels and 32 recording channels, providing high precision and targeted brain activity recording. Developed in collaboration with mBrainTrain LLC.

Adults Segment to Dominate the Transcranial Magnetic Stimulation System Market

The adult segment is expected to grow in the global transcranial magnetic stimulation system market, primarily due to this group's high prevalence of mental health disorders like depression and anxiety. The primary users of transcranial magnetic stimulation therapy are adults; the majority of them fall in the age group of 18-65 years. Growing prevalence of treatment-resistant depression, combined with increasing acceptance of non-invasive treatment procedures among adults. Furthermore, owing to the growing awareness about its safety and efficacy as an alternative to traditional treatments, and in consideration of favorable insurance coverage and accessibility to specialized care facilities, this segment enjoys dominance in the market.

For instance, in June 2024, BrainsWay Ltd. announced that the USFDA has granted for its Deep Transcranial Magnetic Stimulation (Deep TMS) system, now approved for the treatment of major depressive disorder in patients aged 22 to 86, extending the previous age limit of 68. BrainsWay Deep TMS is the first TMS treatment indicated for patients over 68 years old with MDD, including those with comorbid anxiety symptoms.

North America Dominates the Transcranial Magnetic Stimulation System Market

North America leads the market in the transcranial magnetic stimulation system because of the prevalence of mental health disorders in this region. Approximately 19.86% of United States adults live with a mental health condition, and 46% are expected to experience one during their lifetime. Over 20% of youth have faced a seriously debilitating mental condition, while around 5% of adults experience serious mental illness, driving demand for advanced treatments like TMS systems, increased adoption of advanced technologies in treatment, and established healthcare infrastructure. Moreover, the growing demand for non-invasive treatment options for conditions such as depression and anxiety, combined with government initiatives promoting mental health care, is growing the transcranial magnetic stimulation market. For instance, in January 2024, Magstim, Inc. received FDA clearance for its Horizon 3.0 system with StimGuide Pro, offering advanced TMS technology for treating depression and obsessive-compulsive conditions. The system features a user-friendly interface with Bluetooth anatomical mapping and precise treatment targeting through integrated camera technology. TMS uses electromagnetic coils to stimulate brain regions involved in mood control and depression.

Future Market Scenario (2025-2032F)

The global transcranial magnetic stimulation system market looks promising, aided by growing mental health awareness, technological advancements, and expanding therapeutic applications. The increased investment into research and development should unlock new opportunities for TMS as a treatment for increasingly broader neurological and psychiatric disorders. Significant growth potential as healthcare infrastructure improves and the demand for non-invasive treatment solutions grows. In addition, integrating artificial intelligence and machine learning to enhance the precision of treatment and patient outcomes will possibly reshape the transcranial magnetic stimulation system market. For instance, in August 2024, Neuronetics, Inc. announced an all-stock acquisition of Greenbrook TMS Inc., creating a vertically integrated organization focused on developing TMS technology. Neuronetics, based in Malvern, Pennsylvania, is known for its NeuroStar system, which uses a coil-based design for immediate depression treatment. Greenbrook, in addition to offering TMS therapy, provides Spravato nasal spray for depression, further expanding the combined company's portfolio in the neuro health market.

Key Players Landscape and Outlook

The transcranial magnetic stimulation system market is segmented into types and age-related patient treatment. The type segment is fragmented with numerous providers, while market players lead the type segment. Recent developments include advanced product launches, treatment center expansions, and strategic mergers and partnerships.

For instance, in May 2022, neurocare group AG announced the approval of its Apollo TMS system for depression treatment by the Therapeutic Goods Administration (TGA) in Australia. The system will be launched at the Royal Australian & New Zealand College of Psychiatry (RANZCP) Congress in Sydney. TMS has recently been included in the Medicare Benefits Schedule for patients with treatment-resistant depression under psychiatric care, further boosting the market potential for Apollo TMS in Australia.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Transcranial Magnetic Stimulation System Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Deep Transcranial Magnetic Stimulation
    • 4.2.1.2. Repetitive Transcranial Magnetic Stimulation
    • 4.2.1.3. Others
  • 4.2.2. By Application
    • 4.2.2.1. Epilepsy
    • 4.2.2.2. Depression
    • 4.2.2.3. Alzheimer's Disease
    • 4.2.2.4. Parkinson's Disease
    • 4.2.2.5. Others
  • 4.2.3. By Age Group
    • 4.2.3.1. Children
    • 4.2.3.2. Adults
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals
    • 4.2.4.2. Clinics
    • 4.2.4.3. Ambulatory Surgical Centers
    • 4.2.4.4. Diagnostic Centers
    • 4.2.4.5. Others
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia-Pacific
    • 4.2.5.4. South America
    • 4.2.5.5. Middle East and Africa
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Type
  • 4.3.2. By Application
  • 4.3.3. By Age Group
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. North America Transcranial Magnetic Stimulation System Market Outlook, 2018-2032F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Type
    • 5.2.1.1. Deep Transcranial Magnetic Stimulation
    • 5.2.1.2. Repetitive Transcranial Magnetic Stimulation
    • 5.2.1.3. Others
  • 5.2.2. By Application
    • 5.2.2.1. Epilepsy
    • 5.2.2.2. Depression
    • 5.2.2.3. Alzheimer's Disease
    • 5.2.2.4. Parkinson's Disease
    • 5.2.2.5. Others
  • 5.2.3. By Age Group
    • 5.2.3.1. Children
    • 5.2.3.2. Adults
  • 5.2.4. By End-user
    • 5.2.4.1. Hospitals
    • 5.2.4.2. Clinics
    • 5.2.4.3. Ambulatory Surgical Centers
    • 5.2.4.4. Diagnostic Centers
    • 5.2.4.5. Others
  • 5.2.5. By Country Share
    • 5.2.5.1. United States
    • 5.2.5.2. Canada
    • 5.2.5.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Transcranial Magnetic Stimulation System Market Outlook, 2018-2032F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Type
        • 5.3.1.2.1.1. Deep Transcranial Magnetic Stimulation
        • 5.3.1.2.1.2. Repetitive Transcranial Magnetic Stimulation
        • 5.3.1.2.1.3. Others
      • 5.3.1.2.2. By Application
        • 5.3.1.2.2.1. Epilepsy
        • 5.3.1.2.2.2. Depression
        • 5.3.1.2.2.3. Alzheimer's Disease
        • 5.3.1.2.2.4. Parkinson's Disease
        • 5.3.1.2.2.5. Others
      • 5.3.1.2.3. By Age Group
        • 5.3.1.2.3.1. Children
        • 5.3.1.2.3.2. Adults
      • 5.3.1.2.4. By End-user
        • 5.3.1.2.4.1. Hospitals
        • 5.3.1.2.4.2. Clinics
        • 5.3.1.2.4.3. Ambulatory Surgical Centers
        • 5.3.1.2.4.4. Diagnostic Centers
        • 5.3.1.2.4.5. Others
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Transcranial Magnetic Stimulation System Market Outlook, 2018-2032F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Transcranial Magnetic Stimulation System Market Outlook, 2018-2032F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Transcranial Magnetic Stimulation System Market Outlook, 2018-2032F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Transcranial Magnetic Stimulation System Market Outlook, 2018-2032F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals
• 17.3. Innovations

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Nexstim Plc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. eNeura Inc.
  • 20.3.3. Magstim, Inc.
  • 20.3.4. TERUMO BCT, INC.
  • 20.3.5. Arthrex, Inc.
  • 20.3.6. neurocare group AG
  • 20.3.7. Neuronetics, Inc.
  • 20.3.8. Axilum Robotics SAS
  • 20.3.9. Orchid Medical Centre
  • 20.3.10. Medtronic plc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer